A1M Pharma: Orphan Drug Designation granted in Europe for A1M Pharma’s treatment for preeclampsia

The European Commission has granted formal approval for A1M Pharma’s application for Orphan Drug Designation in Europe regarding the company’s treatment for preeclampsia.In May 2014, the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) announced its approval of A1M Pharma’s application for Orphan Drug Designation in Europe. This meant that COMP recommended the European Commission to grant formal Orphan Drug Designation, and the European Commission has now formally approved A1M Pharma’s application for Orphan Drug Designation for the treatment of preeclampsia.